Abstract: The invention relates to a pharmaceutical composition, methods for its use and kits comprising the pharmaceutical composition, wherein the composition comprises: (a) a carrier portion; (b) a targeting portion, wherein said targeting portion comprises a targeting peptide; and (c) an immune response triggering portion, wherein said immune response triggering portion triggers a complement mediated hyperacute immune response.

Abstract: The present invention provides a vector system which can be stably translocated from the cytoplasm of a cell to the nucleus where it is a stable nuclear episomal vector. A basic vector system according to the present invention is generally composed of nucleic acid encoding (a) a promoter functional both in cytoplasm and nucleus, operably linked to (b) a plasmid maintenance/translocation factor and (c) an origin of replication.

Abstract: The inventive vector specifically directs entry into a cell of monocytic origin. The vector is composed of a nucleic acid component, a lysosome evading component and a particle that can be phagocytized. The vector itself, or cells pretreated with the vector, are useful in all gene medicine applications. Because it is specific for monocytic cells, the inventive vector is particularly suited to vaccine applications. Due to the ability of monocytic cells to target tumors, the inventive vector also is suitable for use in anti-tumor applications, including conventional gene therapy.

Abstract: The invention relates to a pharmaceutical composition, methods for its use and kits comprising the pharmaceutical composition, wherein the composition comprises: (a) a carrier portion; (b) a targeting portion, wherein said targeting portion comprises a targeting peptide; and (c) an immune response triggering portion, wherein said immune response triggering portion triggers a complement mediated hyperacute immune response.

Abstract: The present invention provides compositions and methods for slowing tumor growth, decreasing cell proliferation, decreasing neovascularization and blocking metastatic spread using highly sulfated oligosaccharides. The compositions described herein are useful for cancer therapy and may be optionally complexed to at least one therapeutic agent.

Abstract: The present invention provides a vector system which can be stably translocated from the cytoplasm of a cell to the nucleus where it is a stable nuclear episomal vector. A basic vector system according to the present invention is generally composed of nucleic acid encoding (a) a promoter functional both in cytoplasm and nucleus, operably linked to (b) a plasmid maintenance/translocation factor and (c) an origin of replication.

Abstract: The inventive vector specifically directs entry into a cell of monocytic origin. The vector is composed of a nucleic acid component, a lysosome evading component and a particle that can be phagocytized. The vector itself, or cells pretreated with the vector, are useful in all gene medicine applications. Because it is specific for monocytic cells, the inventive vector is particularly suited to vaccine applications. Due to the ability of monocytic cells to target tumors, the inventive vector also is suitable for use in anti-tumor applications, including conventional gene therapy.